Medshine Discovery Inc. has divulged benzospiroheterocyclic derivatives acting as prostaglandin E receptor 4 (PTGER4; EP4 receptor) antagonists reported to be useful for the treatment of cancer.
Glycomimetics Inc. has identified glycosides acting as galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, inflammation, thrombosis, cardiovascular disorders, transplant rejection, neurodegeneration, fibrosis and liver diseases, among other disorders.
Hibercell Inc. has disclosed aminopyrimidine derivatives acting as phosphatidylinositol 5-phosphate 4-kinase type II α (PIP4K2A; PIP5K2A) and type II β (PIP4K2B; PIP5K2B) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, inflammation and metabolic diseases.
Pharmablock Sciences (Nanjing) Inc. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of inflammation and autoimmune disease.
Shenzhen Chipscreen Biosciences Ltd. has identified heterocyclic compounds acting as thyroid hormone receptor (THR) β agonists expected to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes, obesity, hyperlipidemia, hypothyroidism, atherosclerosis, thyroid cancer and hypercholesterolemia, among others.
Shanghai Raising Pharmaceutical Co. Ltd. has synthesized prodrugs of thiamine acting as amyloid-β (Aβ) protein production inhibitors reported to be useful for the treatment of neurodegenerative diseases, preferably Alzheimer's disease (AD).
RSS